Real-world Study of Dedifferentiated Liposarcoma Patients in China

Boehringer Ingelheim1,390 enrolled

Overview

This study will characterize patients with dedifferentiated liposarcoma (DDLPS) in China, including an understanding of demographic, and clinical characteristics as well as treatment patterns and clinical outcomes associated with the current real-world treatment.

Study Type

OBSERVATIONAL

Enrollment

1,390

Conditions

Dedifferentiated Liposarcoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Patient has two or more documented clinical visits in the National Anti-Tumor Drug Surveillance System (NATDSS) network on or after January 1, 2013. * Patient has a confirmed diagnosis of dedifferentiated liposarcoma (DDLPS) during his/her lifetime. * At least 18 years old at the date of initial diagnosis. No exclusion criteria are applied.

Locations (1)

Beijing Jishuitan hospital

Beijing, China

Outcomes

Primary Outcomes

Cohort 1: Overall Survival

Overall survival (OS) as an event for each patient in Cohort 1 was defined as the date of death minus the index date or the start day of each line of therapy (LOT). For patients with no record of death, OS was censored at the last activity date before the end of the study period.

Time frame: Time from index date until the earliest record of death or end of the study period, up to 10 years.

Secondary Outcomes

Cohort 1, Cohort 2: Survival After Initial Diagnosis

Survival after initial diagnosis for each patient was defined as the date of death minus the date of initial diagnosis. For patients with no record of death, survival after initial diagnosis was censored at the last activity date before the end of the study period.

Time frame: Time from initial diagnosis until the earliest record of death or end of the study period, up to 10 years.

Cohort 1, Cohort 2: Total Number of Treatment Lines

The total number of treatment lines in both cohorts is reported. Lines of therapy (LOT) were defined by the temporal relationship and sequencing of treatment regimens by using the dates of initiation and discontinuation of chemotherapy, targeted therapy, and/or immunotherapy.

Time frame: At index date and during follow-up, up to 10 years.

Cohort 1, Cohort 2: First Line (1L) of Therapy by Treatment Type

Number of patients with first line (1L) therapy by treatment type for both cohorts is reported. Lines of therapy (LOT) were defined by the temporal relationship and sequencing of treatment regimens by using the dates of initiation and discontinuation of chemotherapy, targeted therapy, and/or immunotherapy.

Time frame: At index date and during follow-up, up to 10 years

Cohort 1, Cohort 2: Second Line (2L) of Therapy by Treatment Type

Number of patients with second line (2L) therapy by treatment type for both cohorts is reported. Lines of therapy (LOT) were defined by the temporal relationship and sequencing of treatment regimens by using the dates of initiation and discontinuation of chemotherapy, targeted therapy, and/or immunotherapy.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.